

Rabbit anti MEK1/2 Antibody

Alternate Names: MAPKK1/2, MEK1/2.

ANTIGEN PREPARATION

A synthetic peptide corresponding to internal sequence of human MEK1/2. This sequence is identical among human, rat, mouse, chicken.

BACKGROUND

The MEK1 & 2 (MAPKK1/2) are members of tyrosine/threonine protein kinase family that activate the ERK1+2/MAPK enzymes by phosphorylation. MEK 1 + 2 are also activated by dual-phosphorylation, which occurs on serine 218 and 222, in the activation loop of the MEKs. The MEK1 & 2 are regulated by phosphorylation by one of the MEK kinases.

PURIFICATION

The Rabbit IgG is purified by Site-specific Epitope Affinity Purification.

SPECIFICITY

This antibody recognizes ~44/45 kDa of human MEK1/2 protein. This antibody also reacts with mouse and rat, chicken. The other species are not tested.

APPLICATIONS/SUGGESTED WORKING DILUTIONS

Western Blot	0.1-1 µg/ml
ELISA	0.01-0.1 µg/ml
Immunoprecipitation	2-5 µg/ml
IHC	Not tested
Flow cytometry	Not tested

<u>O</u>	rder Information
Description: Rat	bbit anti-MEK1/2
Catalogue#:	<u>500-7854</u>
Lot#:	See the label
Size:	<u>100 ug/200 ul</u>
Host:	Rabbit
Clone:	N/A
Application:	ELISA, WB
Reactivity:	Hu, Ms, Rt, Ck

FORMULATION

This affinity purified antibody is supplied in sterile Phosphatebuffered saline (pH7.2) containing antibody stabilizer


STORAGE

The antibodies are stable for 12 months from date of receipt when stored at -20° C to -70° C. The antibodies can be stored at 2° C-8°C for three month without detectable loss of activity. Avoid repeated freezing-thawing cycles.

MOLECULAR WEIGHT:	44 kDa
POSITIVE CONTROL:	зтз
CELLULAR LOCATION:	N/A

Optimal dilutions should be determined by researchers for the specific applications.

DATA ATTACHMENTS



Western Blot:
The whole cell lysates
derived from 3T3 were
immunoblotted by
Rabbit anti-MEK1/2
(Cat#500-7854) at
1:1000 .

REFERENCES

Ali R. Jazirehi, et al. Inhibition of the Raf–MEK1/2–ERK1/2 Signaling Pathway, Bcl-xL Down-Regulation, and Chemosensitization of Non-Hodgkin's Lymphoma B Cells by Rituximab. CANCER RESEARCH 64, 7117–7126, October 1, 2004

FOR RESEARCH USE ONLY.